World Patient Safety Summit is Sold Out But Space is Available at the Breakout Sessions, Held the Day after the World Summit, at the Royal Society in London
The latest advances in vaccine safety, reducing unnecessary C-sections and person & patient engagement will be among the varied breakout sessions offered the day after the 6th Annual World Patient Safety, Science & Technology Summit in London by the Patient Safety Movement Foundation. The breakout sessions will convene on Sunday, February 25, 2018 at the prestigious Royal Society, the independent scientific academy of the United Kingdom and the Commonwealth, dedicated to promoting excellence in science.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180219005119/en/
Limited Space available to participate with experts at the 6th Annual World Patient Safety, Science & Technology Summit Break Out Sessions at the Royal Society in London (Photo: Business Wire)
The breakout sessions are full-day working meetings structured for shared learning on existing Actionable Patient Safety Solutions (APSS) – collaborative, evidence-based processes that show results in patient safety – and for developing new APSS. These sessions provide healthcare professionals, advocates, and enthusiasts the opportunity to contribute their experiences and expertise, which is critical to process improvement, while also promoting transparency and encouraging aligned incentives that will eventually lead to ZERO preventable patient deaths in hospitals by 2020.
The World Patient Safety, Science & Technology Summit, and Breakout Sessions are supported by the Rt. Hon Jeremy Hunt, MP, Secretary of State for Health and Social Care, Department of Health United Kingdom and co-convened by the European Society of Anaesthesiology. This year’s breakout sessions will include:
Many healthcare institutions can improve patient safety through procedures related to immunization, safety monitoring, and pertinent participatory information systems. This session will exchange the latest advances in patient and vaccine safety research methods, and pertinent key performance indicators for healthcare institutions. Finally, the group will crystallize the plans for developing an Actionable Patient Safety Solutions (APSS) that focuses on safeguarding patients through engagement, protecting the providers caring for patients, and shielding at-risk patients. Other key topics of discussion will include systematic monitoring of adverse events and feedback knowledge updates for healthcare providers.
Person and Family Engagement (PFE)
Person and Family Engagement is an underused “natural resource” for improving patient safety. Ample evidence has accumulated which demonstrates that when patients are actively engaged partners, they achieve better outcomes and help produce innovative solutions. Persons who use care or manage its use for loved ones are highly motivated to partner with professional and organizational care providers to drive change across the care continuum. Their experiences bring an urgency to the patient safety movement that propels action by generating empathy – they engage our hearts as well as our minds and hands.
Injuries related to falls impose a catastrophic cost of care on families and healthcare economics. Fall prevention and injury reduction require a collaborative approach involving leadership, clinical intervention, and patent and family partnership. This session will explore the Actionable Patient Safety Solutions for Fall Prevention and Injury Reduction. The latest research and science will be discussed along with revisions to the APSS that can assist in care that reduces harm, injury, and death.
Driving Sustainable Change in Hand Hygiene - The Problem We Only THINK We Solved
If hand hygiene is the most effective way to prevent avoidable HAIs, why is global compliance below 50%? Recent studies prove that three elements are essential for sustainable improvement: Accurate measurement, evidence-based feedback, and top-down accountability. The current hand hygiene APSS incorporates this learning into actionable guidelines. Attendees will learn how to translate emerging science into action by providing input into the APSS through sharing experience & knowledge.
Reducing Unnecessary C-Sections
One of the life-altering procedures of modern obstetrics is the performance of an appropriately timed and executed cesarean delivery and yet over performance can lead to short and long-term complications and maternal deaths. In parts of the world increased cesarean section rates are associated with rising maternal mortality rates. Therefore, the avoidance of performing unnecessary cesarean births has become an important long-term strategy in reducing maternal mortality.
Sepsis is a growing issue worldwide. This session will review and discuss the latest APSS #9A: Early Detection & Treatment of Sepsis for High-income Countries and the new APSS #9B: Early Detection & Treatment of Sepsis for Low and Middle-income Countries. Participants will share ideas and make suggestions to improve the APSS based on their knowledge and experience. The goal of the working group session is to facilitate revisions that increase APSS effectiveness and identify ways to disseminate APSSs more widely.
Should drug shortages be viewed as a patient safety issue? That is one of the issues the working group will tackle in this session. Pharmaceutical shortages have a profound effect on clinical practice and patient outcomes and increase health care costs. The objectives of the session are to understand the reasons for drug shortages and define alternatives for shortage prevention and mitigation. Participants will also discuss the role of technology in coming up with solutions.
For more information on the breakout sessions, or to register, please visit http://www.cvent.com/events/6th-annual-world-patient-safety-science-technology-summit/event-summary-354a3027b4904b42940fda0fc321463f.aspx.
About Patient Safety Movement Foundation:
More than 200,000 U.S. patients and three million worldwide die each year from preventable causes. The Patient Safety Movement Foundation (PSMF) was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to zero by 2020 (0X2020). Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The PSMF works with all stakeholders to address problems with actionable solutions. The Foundation also convenes the World Patient Safety, Science and Technology Summit bringing together some of the world’s best minds for thought-provoking discussions and new ideas that challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.
Patient Safety Movement Foundation
Tanya Lyon, (949) 351-2858
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 21:28 | Tiedote
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05 | Tiedote
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52 | Tiedote
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50 | Tiedote
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00 | Tiedote
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme